Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"
Jump to navigation
Jump to search
| (12 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[Image:Adenocarcinoma_-_ROS1_positive_-_ROS1_--_high_mag.jpg|thumb|right|[[Micrograph]] showing a ROS1-positive [[adenocarcinoma of the lung]]. ROS1 [[immunostain]].]] | |||
'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref> | '''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref> | ||
==General== | ==General== | ||
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal | | *ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |authors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref> | ||
*Respond to | *Respond to targeted therapy, e.g. [[crizotinib]].<ref name=pmid30980071>{{cite journal |authors=Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI |title=Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 |journal=Ann. Oncol. |volume=30 |issue=7 |pages=1121–1126 |date=July 2019 |pmid=30980071 |pmc=6637370 |doi=10.1093/annonc/mdz131 |url=}}</ref> | ||
==Microscopic== | |||
Features: | |||
*Histology not definitive; however, predictive features are:<ref name=pmid27648828/> | |||
**[[Cribriform structure]]. | |||
**[[Psammoma bodies]] | |||
Note: | |||
*Most common pattern varies by specimen type:<ref name=pmid27648828>{{cite journal |authors=Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J |title=A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features |journal=PLoS ONE |volume=11 |issue=9 |pages=e0161861 |date=2016 |pmid=27648828 |pmc=5029801 |doi=10.1371/journal.pone.0161861 |url=}}</ref> | |||
**Biopsy specimens: solid pattern most common. | |||
**Resection specimens: acinar pattern most common. | |||
===Images=== | |||
<gallery> | |||
Image: Adenocarcinoma - ROS1 positive -- low mag.jpg | NSmCC - low mag. | |||
Image: Adenocarcinoma - ROS1 positive -- intermed mag.jpg | NSmCC - intermed. mag. | |||
Image: Adenocarcinoma - ROS1 positive -- high mag.jpg | NSmCC - high mag. | |||
Image: Adenocarcinoma - ROS1 positive -- very high mag.jpg | NSmCC - very high mag. | |||
Image: Adenocarcinoma - ROS1 positive - TTF1 -- high mag.jpg | NSmCC - TTF-1 - high mag. | |||
Image: Adenocarcinoma - ROS1 positive - napsin A -- high mag.jpg | NSmCC - napsin A - high mag. | |||
</gallery> | |||
==IHC== | |||
*ROS1 +ve. | |||
===Images=== | |||
<gallery> | |||
Image: Adenocarcinoma - ROS1 positive - ROS1 -- low mag.jpg | NSmCC - ROS1 - low mag. | |||
Image: Adenocarcinoma - ROS1 positive - ROS1 -- intermed mag.jpg | NSmCC - ROS1 - intermed. mag. | |||
Image: Adenocarcinoma - ROS1 positive - ROS1 -- high mag.jpg | NSmCC - ROS1 -high mag. | |||
</gallery> | |||
==Molecular== | |||
*ROS1 rearrangements can be demonstrated with dual-colour break apart [[FISH]] probes.<ref name=pmid27535289>{{cite journal |authors=Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E |title=Testing for ROS1 in non-small cell lung cancer: a review with recommendations |journal=Virchows Arch. |volume=469 |issue=5 |pages=489–503 |date=November 2016 |pmid=27535289 |pmc=5082594 |doi=10.1007/s00428-016-2000-3 |url=}}</ref> | |||
==See also== | ==See also== | ||
| Line 11: | Line 48: | ||
==References== | ==References== | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Diagnosis]] | [[Category:Diagnosis]] | ||
[[Category:Molecular pathology]] | |||
Latest revision as of 20:25, 24 May 2020
ROS1-rearranged non-small cell lung carcinoma is a subtype of non-small cell lung carcinoma that can be treated with ALK inhibitors.[1]
General
- ROS1-rearrangements are seen in approximately 1-2% of non-small cell carcinoma.[2]
- Respond to targeted therapy, e.g. crizotinib.[3]
Microscopic
Features:
- Histology not definitive; however, predictive features are:[4]
Note:
- Most common pattern varies by specimen type:[4]
- Biopsy specimens: solid pattern most common.
- Resection specimens: acinar pattern most common.
Images
NSmCC - low mag.
NSmCC - intermed. mag.
NSmCC - high mag.
NSmCC - very high mag.
NSmCC - TTF-1 - high mag.
NSmCC - napsin A - high mag.
IHC
- ROS1 +ve.
Images
NSmCC - ROS1 - low mag.
NSmCC - ROS1 - intermed. mag.
NSmCC - ROS1 -high mag.
Molecular
See also
References
- ↑ Shaw, AT.; Ou, SH.; Bang, YJ.; Camidge, DR.; Solomon, BJ.; Salgia, R.; Riely, GJ.; Varella-Garcia, M. et al. (Nov 2014). "Crizotinib in ROS1-rearranged non-small-cell lung cancer.". N Engl J Med 371 (21): 1963-71. doi:10.1056/NEJMoa1406766. PMID 25264305.
- ↑ Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW (October 2019). "Targeted therapies for ROS1-rearranged non-small cell lung cancer". Drugs Today 55 (10): 641–652. doi:10.1358/dot.2019.55.10.3030646. PMID 31720561.
- ↑ Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI (July 2019). "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001". Ann. Oncol. 30 (7): 1121–1126. doi:10.1093/annonc/mdz131. PMC 6637370. PMID 30980071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637370/.
- ↑ 4.0 4.1 Zhou J, Zhao J, Zheng J, Kong M, Sun K, Wang B, Chen X, Ding W, Zhou J (2016). "A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features". PLoS ONE 11 (9): e0161861. doi:10.1371/journal.pone.0161861. PMC 5029801. PMID 27648828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029801/.
- ↑ Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E (November 2016). "Testing for ROS1 in non-small cell lung cancer: a review with recommendations". Virchows Arch. 469 (5): 489–503. doi:10.1007/s00428-016-2000-3. PMC 5082594. PMID 27535289. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082594/.